Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

NCT01931566 PHASE3 TERMINATED Results posted

The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.

Details

Lead sponsor	Takeda
Phase	PHASE3
Status	TERMINATED
Enrolment	3494
Start date	Thu Aug 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Sep 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

• Pioglitazone
• Pioglitazone placebo

Countries

United Kingdom, Germany, Switzerland, Australia, United States